Cannabinoids

Publication Title: 
Headache

Hallucinogens and most cannabinoids are classified under schedule 1 of the Federal Controlled Substances Act 1970, along with heroin and ecstacy. Hence they cannot be prescribed by physicians, and by implication, have no accepted medical use with a high abuse potential. Despite their legal status, hallucinogens and cannabinoids are used by patients for relief of headache, helped by the growing number of American states that have legalized medical marijuana.

Author(s): 
McGeeney, Brian E.
Publication Title: 
The Journal of Nervous and Mental Disease

Patients using medical cannabis in the United States inhabit a conflicting medicolegal space. This study presents data from a dispensary-based survey of patients using medical cannabis in the state of Washington regarding cannabis-specific health behaviors, levels of psychological distress, stress regarding marijuana criminality, past experiences with drug law enforcement, and coping behaviors. Thirty-seven subjects were enrolled in this study, and all but three completed survey materials.

Author(s): 
Aggarwal, Sunil Kumar
Carter, Gregory
Sullivan, Mark
Morrill, Richard
Zumbrunnen, Craig
Mayer, Jonathan
Publication Title: 
Médecine Sciences: M/S

Originally used in Asia for the treatment of pain, spasms, nausea and insomnia, marijuana is the most consumed psychotropic drug worldwide. The interest of medical cannabis has been reconsidered recently, leading to many scientific researches and commercialization of these drugs. Natural and synthetic cannabinoids display beneficial antiemetic, anti-inflammatory and analgesic effects in numerous diseases, however accompanied with undesirable effects due to the CB1 receptor.

Author(s): 
Leleu-Chavain, Natascha
Biot, Christophe
Chavatte, Philippe
Millet, Régis
Publication Title: 
Epilepsia

To present a summary of current scientific evidence about the cannabinoid, cannabidiol (CBD) with regard to its relevance to epilepsy and other selected neuropsychiatric disorders. We summarize the presentations from a conference in which invited participants reviewed relevant aspects of the physiology, mechanisms of action, pharmacology, and data from studies with animal models and human subjects. Cannabis has been used to treat disease since ancient times.

Author(s): 
Devinsky, Orrin
Cilio, Maria Roberta
Cross, Helen
Fernandez-Ruiz, Javier
French, Jacqueline
Hill, Charlotte
Katz, Russell
Di Marzo, Vincenzo
Jutras-Aswad, Didier
Notcutt, William George
Martinez-Orgado, Jose
Robson, Philip J.
Rohrback, Brian G.
Thiele, Elizabeth
Whalley, Benjamin
Friedman, Daniel
Publication Title: 
Adolescent Medicine: State of the Art Reviews

Marijuana use in pediatric populations remains an ongoing concern, and marijuana use by adolescents had known medical, psychological, and cognitive side effects. Marijuana alters brain development and has detrimental effects on brain structure and function in ways that are incompletely understood at this point in time. Furthermore, marijuana smoke contains tar and other harmful chemicals, so marijuana cannot be recommended by physicians. At this time, no studies suggest a benefit of marijuana use by children and adolescents.

Author(s): 
Ammerman, Seth
Publication Title: 
Journal of Safety Research

OBJECTIVE: To determine if cannabinoid prevalence increased among fatal-crash-involved drivers in 12 U.S. states after implementing medical marijuana laws. METHODS: Time series analyses of 1992 to 2009 driver cannabinoid prevalence from the Fatality Analysis Reporting System. RESULTS: Increased driver cannabinoid prevalence associated with implementing medical marijuana laws was detected in only three states: California, with a 2.1 percentage-point increase in the percentage of all fatal-crash-involved drivers who tested positive for cannabinoids (1.1% pre vs.

Author(s): 
Masten, Scott V.
Guenzburger, Gloriam Vanine

Pages

Subscribe to RSS - Cannabinoids